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Supplementary Information 1 
 2 
 3 
Supplementary Materials and Methods 4 
Reagents 5 
Exendin-4 (GLP-1R agonist), exendin- 9-39 (GLP-1R antagonist), ouabain (specific Na
+
 K
+
 6 
ATPase inhibitor), 3-Isobutyl-1-methylxanthine (IBMX; phosphodiesterase inhibitor) and 7 
Forskolin (adenylate cyclase activator) were purchased from Sigma-Aldrich. For the in vivo 8 
studies exendin 9-39 was purchased from Cohesion Biosciences (CCP1199) and Abcam 9 
(ab141101). Fluorescently tagged exendin-4 (FLEX) was purchased from AnaSpec (AS-10 
63899). The myristoylated PKA inhibitor (PKI)–(14-22)-amide was purchased from Merck 11 
Chemicals. Mouse monoclonal antibody against human GLP-1R protein was purchased from 12 
the Developmental Studies Hybridoma Bank (Iowa; Mab 3F52, deposited by Knudsen, L.B.). 13 
Primary antibodies for choroid plexus epithelial (CPe) cell characterization included antibodies 14 
against transthyretin (TTR; sheep, ab9015, Abcam), Na
+
 K
+
 ATPase (rabbit, ab76020, Abcam; 15 
mouse, 05-369, Millipore), zona occludens-1 (ZO-1; rabbit, 61-7300, Life Technologies), 16 
aquaporin 1 (AQP1; rabbit, AB3065, Abcam; rabbit, AB2219, Millipore) and β-actin (mouse, 17 
A5441, Sigma Aldrich). For immunohistochemistry, the Alexa Fluor
®
 labelled secondary 18 
antibodies were purchased from Life Technologies and for western blot, HRP-conjugated 19 
secondary antibodies were bought from Cell Signaling Technology. Cell culture reagents were 20 
from Life Technologies or Sigma-Aldrich and unless specified all other chemicals were 21 
purchased from Sigma-Aldrich. For surgical procedures the midazolam was purchased from B. 22 
Braun and the fluanisone and fentanylcitrate from the Danish pharmacy supply. 23 
 24 
In vitro experiments  25 
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Whole Choroid plexus. The choroid plexus from the lateral ventricles were dissected and 26 
placed in artificial CSF (aCSF; 118mM NaCl, 22mM NaHCO3, 1.45mM K2HPO4, 1mM 27 
MgSO4, 1mM CaCl2 and 10mM glucose). To evaluate the effects of exendin-4 ondemonstrate 28 
the presence of the GLP-1R localisation within the cellin the choroid plexus, whole choroid 29 
plexus was incubated with aCSF containing (a) 1µM FLEX for 15 and 30 minutes or (b) 1µM 30 
exendin 9-39 for 10 minutes followed by 1µM FLEX for 30 minutes. 100nM Exendin-9-39 for 31 
15 minutes followed by 100nM exendin-4 for 30 minutes or 100nM exendin-4 only for 15 and 32 
30 minutes. Whole choroid plexus was then fixed and visualized under a Zeiss LSM 510 UV-33 
confocal microscope (Carl Zeiss)stained following the protocol described below. To determine 34 
the effects of exendin-4 on GLP-1R mRNA expression the choroid plexus was incubated with 35 
aCSF containing 100nM exendin-4 for 3 and 6 hours, immediately frozen in liquid nitrogen 36 
and stored at -80⁰C. 37 
 38 
Primary CPe cell culture. Choroid plexus tissue from lateral and fourth ventricles were 39 
dissected and incubated with 0.25% trypsin solution for 2.5 hours at 4°C followed by 30 40 
minutes at 37°C. Trypsin digestion was stopped by the addition of newborn calf serum and the 41 
cell suspension was centrifuged at 20g for 10 minutes. Cells were resuspended in DMEM/F12 42 
supplemented with 10% FBS, 1% penicillin/streptomycin, 4mM L-glutamine, 200ng/ml 43 
hydrocortisone, 5ng/ml sodium selenite and 10ng/ml EGF. 20µM cytosine arabinoside was 44 
used for the first 4 days in culture to limit the growth of fibroblasts (53). Initially the cells were 45 
seeded onto a laminin coated 6 well plate and allowed to grow for 2 days before being 46 
transferred to laminin coated 96 well plates or 12 well inserts (Greiner Bio-One Ltd). On day 4 47 
the media was replaced with DMEM/F12 supplemented with 10% FBS and 1% 48 
penicillin/streptomycin and changed every 2-3 days. After reaching confluency, CPe cells were 49 
serum deprived for 3 days prior to the beginning of the studies (between days 10-14). 50 
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 51 
Immunofluorescent staining. For staining of rat brain tissue sections, rats were euthanized 52 
with rising CO2 and immediately perfused transcardially with 10mM PBS, pH 7.4 (PBS) 53 
followed by 4% paraformaldehyde (PFA; Alfa Aesar) in PBS. Brains were postfixed overnight 54 
at 4⁰C, cryoprotected by sequential immersion in 10%, 20% and 30% sucrose in PBS at 4⁰C, 55 
embedded in OCT (Fisher Scientific), and 15-µm-thick coronal sections cut on a cryostat 56 
(Bright Instruments), mounted on charged microscope slides and stored at -20⁰C until use. 57 
Sections were first washed in PBST (PBS containing 0.3% Tween20), blocked in PBST 58 
containing 2% bovine serum albumin (BSA) and 15% normal goat serum (NGS) for 20 59 
minutes at room temperature, and then incubated with the primary antibody (PBST with 2% 60 
BSA) at 4°C overnight. After washing in PBST, sections were incubated for 1 hour at room 61 
temperature in the dark with the appropriate Alexa Fluor 488 labelled secondary antibody 62 
diluted in  PBST containing 2% BSA and 1.5% NGS. Finally, sections were washed in PBST 63 
before mounting in Vectashield containing the nuclear stain DAPI (Vector Laboratories).  64 
For fluorescence labelling of CPe cells, samples were first fixed in PBS containing 2% 65 
PFA and 2% glucose for 20 minutes at room temperature, washed in PBS and then 66 
permeabilized with methanol for 6 minutes at room temperature. The cells were stained using 67 
the same technique described above except that PBST was substituted with PBS. 68 
Stained cells and sections were viewed under a Zeiss LSM 510 UV-confocal 69 
microscope (Carl Zeiss) and multiple Z-stack images were taken. 70 
 71 
Immunoperoxidase staining. For staining of paraffin-embedded human choroid plexus, the 72 
sections were dewaxed and dehydrated to distilled water. Sections were treated for 30 minutes 73 
in Tris-EDTA buffer (pH 9.0) at 95ºC in a waterbath for antigen retrieval. The sections were 74 
then cooled in PBST before incubation with 1% H2O2 (70% methanol in PBS) for 30 minutes 75 
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to inhibit endogenous peroxidase. Sections were washed in PBST, blocked in PBST containing 76 
2% BSA and 15% normal serum for 1 hour at room temperature, and then incubated in primary 77 
antibody solution at 4°C overnight. Sections were again washed in PBST before incubation in 78 
biotinylated secondary antibody solution (Vector Laboratories) for 30 minutes at room 79 
temperature. Sections were washed in PBST and then incubated for 30 minutes at room 80 
temperature in Avidin/Biotin Complex (ABC; Vectastain Elite ABC kit, Vector Laboratories) 81 
following the manufacturer’s instructions. After rinsing in PBST, sections were treated with 82 
3’3 diaminobenzidine (DAB) substrate (Vector Laboratories), washed in distilled water, 83 
counterstained with haematoxylin, washed in running water before dehydration, cleared in 84 
xylene and mounted in Vectamount medium (Vector Laboratories).  85 
 86 
Quantitative polymerase chain reaction (qPCR). For qPCR studies the choroid plexus was 87 
dissected, immediately frozen in liquid nitrogen and stored at -80⁰C. Primary cultures of CPe 88 
cells were grown on 12 well inserts until confluency. Total RNA was extracted using the 89 
GenElute mammalian total RNA extraction kit and carried out according to the manufacturer’s 90 
instructions. RNA was reverse transcribed to complementary DNA (cDNA) using a high 91 
capacity reverse transcription kit (Life Technologies) or iScript cDNA synthesis kit (Biorad) 92 
according to the manufacturer’s protocol. Taqman Gene Expression Assays (Life 93 
Technologies) were used to assess the expression of GLP-1R (assay number Rn00562406_m1 94 
and Hs00157705_m1), Na
+
 K
+
 ATPase (assay number Rn01533986_m1), AQP1 (assay 95 
number Rn00562834_m1) and NHE1 (assay number Rn00561924_m1). The 18S ribosomal 96 
subunit was used as an endogenous reference (4319413E) and samples were run in triplicate. 97 
The cycle number at which the particular sample crossed that threshold (Ct) was used to 98 
determine the levels of gene expression and ΔCt was calculated as the difference between the 99 
Ct (gene of interest) and the Ct (endogenous reference). 100 
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 101 
Western blot. The choroid plexus was dissected, immediately frozen in liquid nitrogen and 102 
stored at -80⁰C. Tissues were homogenised in ice cold RIPA lysis buffer and centrifuged at 103 
13,000g to remove cell debris. Tissue lysates (10µg protein) were separated on a 4-12% tris-104 
glycine gel. The proteins were transferred onto a polyvinylidene difluoride membrane and 105 
subsequently blocked with 5% skimmed milk powder in TBST (TBS pH 7.4 with 0.5% 106 
Tween20) for 1 hour at room temperature before incubation with the primary antibody diluted 107 
in milk/TBST overnight at 4⁰C. After washing in TBST the membranes were incubated with 108 
HRP-conjugated secondary antibody diluted in milk/TBST for 1 hour at room temperature. The 109 
bands were detected using ECL reagents (Amersham) and developed onto film. 110 
 111 
cAMP assay. The effect of exendin-4 on the downstream GLP-1R signaling pathway was 112 
assessed by measuring the levels of cAMP in CPe cells using two different techniques. The 113 
first assay was the Amersham cAMP Biotrak Enzyme immunoassay System (RPN 225, GE 114 
Healthcare Life Sciences). CPe cells were grown on a 96 well plate (described previously) and, 115 
on the day of the experiment, incubated in aCSF supplemented with 1mM IBMX containing; 116 
aCSF only (n=8), 100nM exendin-4 (n=8) or 100nM Forskolin (positive control; n=5) for 30 117 
minutes at 37⁰C. The cells were subsequently lysed and cAMP detected according to the 118 
manufacturer’s instructions. The second assay was the LANCE® (Lanthanide chelate excite) 119 
cAMP 384 kit (PerkinElmer). CPe cells were grown in flasks and then trypsinized to form a 120 
single cell suspension. The cells were incubated in stimulation buffer (PBS with 5.5mM 121 
glucose, 0.1% BSA and 0.5mM IBMX) containing; 1nM (n=5), 10nM (n=6) and 100nM 122 
exendin-4 (n=5), with and without 1µM exendin 9-39 (n=6, n=5 and n=5 respectively), and 123 
forskolin (n=6) as a positive control. cAMP was then detected according to the manufacturer’s 124 
instructions.  125 
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 126 
Na
+
 K
+
 ATPase activity assay. The effect of exendin-4 on Na
+
 K
+
 ATPase activity in the 127 
choroid plexus was evaluated by the colorimetric measurement of phosphate released from 128 
ATP hydrolysis with the use of a phosphate assay kit (ab65622, Abcam); with Na
+
 K
+
 ATPase 129 
activity being defined as the portion of phosphate produced that is sensitive to ouabain. CPe 130 
cells were incubated with aCSF for 1 hour at 37⁰C before incubation in aCSF containing; 131 
100nM exendin-4 (n=7), 5µM PKI-16-22-amide (n=8), 100nM exendin-4 + 5µM PKI-16-22-132 
amide (n=8); in the presence and absence of 1mM ouabain for 30 minutes at 37⁰C. The cells 133 
were then lysed on ice and spun at 13,000g to remove cell debris. Phosphate was measured as 134 
per the manufacturer’s instructions. Briefly the reaction mix was added to the samples and 135 
incubated at room temperature for 60 minutes before the plate was read at 690nm. Na
+
 K
+
 136 
ATPase activity was calculated as the difference between the amount of phosphate produced in 137 
the presence and absence of ouabain for each treatment. 138 
 139 
In vivo experiments 140 
Epidural ICP probe implantation. Implantation of an epidural ICP probe and its validation 141 
were recently published as a methodological work that contains all technical and surgical detail 142 
(54). The rats were anaesthetized (2.7ml/kg subcutaneous injection containing 1.25mg/ml 143 
midazolam, 2.5mg/ml fluanisone and 0.079mg/ml fentanylcitrate), placed in a stereotactic 144 
frame (David Kopf Instruments) and a 2cm-midline incision was performed on top of the skull 145 
and the bone was exposed by retracting the skin and soft tissue. A dental drill was used to make 146 
4 burr holes in the skull; one large hole was carefully drilled to expose the dura mater enabling 147 
placement of the epidural ICP probe (C313G-3UP, PlasticsOne), with the cannula cut to be 148 
level with the base of the pedestal. The other 3 smaller holes were used to fit anchoring screws 149 
to the skull. The epidural pressure bolt and the anchoring screws were placed and aligned with 150 
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the interior surface of the skull and secured using dental resin-cement (Clearfil SA Cement, RH 151 
Dental). The epidural ICP probe and the transducer (DTX-Plus™, Argon Medical Devices) 152 
were then connected by a polyethylene tube filled with sterile water, ensuring the absence of 153 
air bubbles. The pressure signal was visualized and recorded using Perisoft v.2.5.5 (Perimed). 154 
Correct ICP signal was confirmed by the transient elevation of ICP after jugular vein 155 
compression. When the ICP recording procedure was completed the epidural pressure cannula 156 
was closed with a bite proof cap (303DCFTX2, PlasticsOne) and the rat allowed to recover.  157 
There was one modification with the epidural ICP probe implantation in the 158 
hydrocephalic rats; before the epidural pressure bolt was placed on the dura, a small hole (1mm 159 
in diameter) was made with forceps in the dura. 160 
 161 
Intracerebroventricular (ICV) injection 162 
During the epidural ICP probe surgery, animals receiving ICV treatments also had an ICV 163 
cannula implanted at the same time. An additional burr hole was made 0.8mm posterior and 164 
1.6mm lateral to Bregma. The cannula was inserted into the left lateral ventricle, fixed with 165 
dental resin-cement and closed by a cap with a dummy cannula to maintain patency. For the 166 
ICV injection rats were anesthetized and connected to the transducer to measure ICP. Once a 167 
stable baseline had been established a 5µl Hamilton syringe connected via tubing to an internal 168 
cannula was used for the ICV injection. 169 
 170 
Osmotic pump implantation 171 
Osmotic pumps (model 1003D, Alzet, Durect Corporation, California, USA) were prepared 172 
under sterile conditions and primed in sterile saline overnight at 37°C to allow prompt delivery 173 
after implantation. The ICV cannula (brain infusion kit 1, Alzet) was set to 4mm and attached 174 
to the pump via 5cm catheter tubing containing saline. The osmotic pump was filled with either 175 
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saline or 4mg/ml exendin 9-39, thus the infusion rate was 4µg/µl/hr (around 100µg per day). 176 
The fluid in the pump and the fluid in the catheter tubing were separated by an air bubble to 177 
delay the start of exendin 9-39 until implantation. 178 
For implantation of the osmotic pump, the head of anaesthetized rat was fixed in a 179 
stereotactic frame, the dorsal skull was exposed and a burr hole sited in the parietal bone 180 
0.8mm posterior and 1.6mm lateral to Bregma. The ICV cannula was inserted into the left 181 
lateral ventricle and fixed in place with glue to 2 stabilising screws (PlasticsOne), and the 182 
osmotic pump was implanted subcutaneously in the neck region. The epidural ICP probe was 183 
then implanted as above. 184 
 185 
Induction of hydrocephalus 186 
We used the kaolin model of hydrocephalus as our model of raised ICP. The rats were 187 
anaesthetized and the head fixed in a stereotactic frame with the neck flexed down in a 90 188 
degree angle to horizontal and secured in this position. A mark was made on the skin above the 189 
dorsal atlanto-occipital membrane between the skull and the first cervical spinosus. The 190 
percutaneous injection was performed using an insulin syringe with a 30 gauge needle, which 191 
was slowly advanced in a vertical direction until there was a loss of resistance and 80 µL of 192 
sterile kaolin suspension (0.250 mg/mL in Ringer’s lactate solution - 1.4mM Ca2+, 4mM K+, 193 
130mM Na
+
, 109mM Cl
-
, 28mM lactate) injected gradually (8.5 µL/s). Following the injection 194 
the neck was extended, the head released from the stereotactic frame and the animal allowed to 195 
recover. 196 
 197 
Blood and electrolyte Measurements. Blood and CSF pH and electrolytes were measured 198 
immediately using an ABL80 FLEX blood gas analyzer (Radiometer Medical ApS). 199 
 200 
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 201 
Fig. S1. Characterisation of primary rat choroid plexus epithelial (CPe) cells in vivo and 202 
in vitro. (A) The identity of CPe cells in culture was determined by immunohistochemistry 203 
using antibodies against: (1) transthyretin (TTR), a CPe cell marker; (2) Na
+
 K
+
 ATPase, ion 204 
pump involved in actively moving Na
+
 out of the CPe cells and into the CSF, (3) zona 205 
occludens-1 (ZO-1), a tight junction protein; and (4) aquaporin 1 (AQP1), the most prominent 206 
water channel in the choroid plexus. TTR staining (green) was observed in the cytoplasm of 207 
the CPe cells; ZO-1 (green) was localised at the interface between the cells indicating the 208 
presence of tight junctions; Na
+
 K
+
 ATPase and AQP1 (green) were present on the apical 209 
surface of the epithelial cells indicating the polarisation of the cells in vitro and in vivo. (B) 210 
The histogram represents the fold change in Glp-1r mRNA from whole choroid plexus + SEM 211 
(choroid plexus n=3; CPe cells n=3), demonstrating Glp-1r mRNA is present in both the CPe 212 
cells and whole choroid plexus. DAPI (blue) was used as a nuclear marker, scale bar - 50µm. 213 
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 214 
Fig. S2. Suggested route for GLP-1 action at the choroid plexus. (A) Under physiological 215 
conditions, GLP-1 is secreted by L cells in response to nutrients in the gut and then enters the 216 
bloodstream or activates the vagus nerve. Therapeutic administration of GLP-1 mimetics is via 217 
a subcutaneous injection. Once in the bloodstream, GLP-1 could bind to GLP-1 receptors 218 
(GLP-1Rs) on the basal surface of the choroid plexus epithelial (CPe) cells or could cross the 219 
blood brain barrier and enter the CSF. Alternatively, the vagus nerve could stimulate GLP-1 220 
production at the nucleus tractus solitarius (NTS), which has fibres projecting to the 221 
hypothalamus (H) adjacent to the CSF. This allows GLP-1 secretion into the CSF, from where 222 
it can bind with GLP-1Rs on the apical surface of the CPe cells. (B) In the kidney proximal 223 
tubule cells, the binding of GLP-1 to its receptor stimulates the conversion of adenosine 224 
triphosphate (ATP) to cyclic adenosine monophosphate (cAMP) by adenylate cyclase (AC) 225 
through Gαs protein subunit. cAMP activates protein kinase A (PKA), which phosphorylates 226 
the Na
+
 H
+
 exchanger resulting in its inhibition, thus preventing Na
+
 reabsorption. (C) We 227 
hypothesize that activation of GLP-1R on choroid plexus epithelial cells stimulates AC, which 228 
converts ATP to cAMP. cAMP subsequently activates PKA which could phosphorylate either 229 
the Na
+
 H
+
 exchanger or the Na
+
 K
+
 ATPase, reducing Na
+
 transport from blood into the CSF. 230 
This would decrease CSF production and potentially reduce ICP. 231 
